Company / PP&E (Net)
ImmunityBio, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$114.3M
FY2025
5-year range
$82.9M / $146.1M
FY2021-FY2025
Trend
-16.7%
vs FY2024
Sector context
#41 of 193
Health Care
What the data says
ImmunityBio, Inc.'s pp&e (net) of $114M is higher than 79% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 10 years, ranging from $19M in FY2016 to $146M in FY2023.
Based on SEC 10-K filings.
$114M in FY2025 with a 5-year CAGR of +9.5%. Top quartile in the Health Care sector.
Declined from $146M to $114M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -7.3%
- 5-Year CAGR
- +9.5%
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 193This company $114.3M Sector average $777.6M
▼
-85.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.5%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 16.7% year-over-year.
- Ranks #41 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.3M | -16.7% |
| FY2024 | $137.1M | -6.2% |
| FY2023 | $146.1M | +1.7% |
| FY2022 | $143.7M | +73.4% |
| FY2021 | $82.9M | +14.2% |
| FY2020 | $72.5M | +19.9% |
| FY2019 | $60.5M | -21.3% |
| FY2018 | $76.9M | +0.2% |
| FY2017 | $76.7M | +305.8% |
| FY2016 | $18.9M | +242.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026